FDA investigates heart risks potentially tied to Xolair

07/16/2009 | WebMD

The FDA is investigating a potential link between Genentech's asthma drug Xolair and a heightened risk of heart and cerebrovascular events. The agency clarified that it "is not advising patients to stop taking Xolair at this time" but urged them to be "aware of the risks and benefits described in the prescribing information."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health